BiotechTube

KAF156

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malaria

Conditions

Malaria

Trial Timeline

Mar 1, 2013 → Aug 1, 2014

NCT ID
NCT01753323

About KAF156

KAF156 is a phase 2 stage product being developed by Novartis for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT01753323. Target conditions include Malaria.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01753323Phase 2Completed

Competing Products

20 competing products in Malaria

See all competitors
ProductCompanyStageHype Score
SAR97276ASanofiPhase 2
51
SJ733 + CobicistatEisaiPhase 1
33
(+)-SJ000557733 (SJ733)EisaiPhase 2
52
E1018 + PlaceboEisaiPhase 1
33
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
33
ZY19489 Capsule + Placebo CapsuleZydus LifesciencesPhase 1
33
M5717 330 mg + M5717 500 mg + M5717 660 mg + Pyronaridine 360 mg + Pyronaridine 360 mg + Pyronaridine 540 mg + Pyronaridine 720 mgMerckPhase 2
52
MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanilMerckPhase 1
33
M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mgMerckPhase 2
52
KLU156 + CoartemNovartisPhase 3
77
KAE609 + IV Artesunate + CoartemNovartisPhase 2
52
KAE609NovartisPhase 2
52
artemether:lumefantrine (2.5 mg:30 mg)NovartisPhase 2/3
65
Artemether-lumefantrine (COA566)NovartisPhase 2/3
65
INE963NovartisPhase 2
52
Ganaplacide + ItraconazoleNovartisPhase 1
33
KAE609 + Piperaquine PhosphateNovartisPhase 1
33
Artemether-lumefantrineNovartisPhase 3
77
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
52
KAF156 + Coartem + Lumefantrine Solid Dispersion FormulationNovartisPhase 2
52

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85